WARRANT TO PURCHASE SHARES OF COMMON STOCK of BOLT BIOTHERAPEUTICS, INC. Dated as of July 26, 2018 Void after the date specified in Section 8Bolt Biotherapeutics, Inc. • September 11th, 2020 • Pharmaceutical preparations • California
THIS CERTIFIES THAT, in consideration of the sum of $ , , or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), shares of the Company’s Common Stock, $0.00001 par value per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the Series B Preferred Stock Purchase Agreement, dated as of July 26, 2018, by and among the Company and the purchasers described therein (the “Purchase Agreement”). The holder of this Warrant is subject to certain restrictions set forth in the Purchase Agreement and the Amended and Restated Investors’ Rights Agreement, dated as of July 26,
SUMMARY OF BASIC LEASE INFORMATIONLease • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
BOLT BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 26, 2020Investors’ Rights Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 26th day of June, 2020 by and among BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
January 26, 2017Bolt Biotherapeutics, Inc. • September 11th, 2020 • Pharmaceutical preparations
LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND BOLT BIOTHERAPEUTICS, INC. (TENANT) SEAPORT CENTRE Redwood City, CaliforniaWorkletter Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
MASTER SERVICES AGREEMENTMaster Services Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations
This Master Services Agreement (together with all signed Statement(s) of Work and signed Change Orders, the “Agreement”) is made and entered into as of June 26, 2018 (the “Effective Date”) by and between Bolt Biotherapeutics, Inc. (“Bolt”), a Delaware corporation with an office at 640 Galveston Drive, Redwood City, CA 94063, U.S.A., and Piramal Healthcare UK Ltd (“Piramal”), a British corporation, with registered office at Whalton Road, Morpeth, Northumberland, NE613YA, UK. Bolt and Piramal hereinafter may be referred to individually as a “Party” or collectively as the “Parties”.
